FDA Approves Olaparib for Frontline Maintenance in Ovarian Cancer

December 19, 2018 – The FDA has approved olaparib as a maintenance treatment for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy, as approved by an FDA-approved companion diagnostic assay. This is the first approval for a PARP inhibitor in the first-line maintenance … (leggi tutto)